Curis

  • Revenue$10.6 MFY, 2021
  • Market Capitalization$90.3 M2022-07-29

OverviewSuggest Edit

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. 

TypePublic
Founded2000
HQLexington, MA, USMap
Websitecuris.com
Employee Ratings4.1
Overall CultureB-More
View Jobs (3)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)31(-43%)
Job Openings3
Revenue (FY, 2021)$10.6 M(-1%)
Share Price (Jul 2022)$1(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Curis

Rachel Blasbalg

Rachel Blasbalg

Senior Director, Human Resources
Kenneth I. Kaitin

Kenneth I. Kaitin

Director
John Hohneker

John Hohneker

Director
James Dentzer

James Dentzer

President and Chief Executive Officer, Director
Lori A. Kunkel

Lori A. Kunkel

Director
Robert Martell

Robert Martell

Head of Research and Development
Show more

Curis Office Locations

Curis has an office in Lexington
Lexington, MA, US (HQ)
4 Maguire Rd
Lexington, MA, US
128 Spring St building c - suite 500
Show all (2)

Curis Financials and Metrics

Curis Revenue

Curis's revenue was reported to be $10.65 m in FY, 2021
USD

Revenue (Q1, 2022)

2.1m

Net income (Q1, 2022)

(16.5m)

EBIT (Q1, 2022)

(15.1m)

Market capitalization (29-Jul-2022)

90.3m

Closing stock price (29-Jul-2022)

1.0

Cash (31-Mar-2022)

18.5m
Curis's current market capitalization is $90.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

14.8m17.0m15.0m9.8m7.9m7.5m9.9m10.4m10.0m10.8m10.6m

Revenue growth, %

(34%)(20%)(4%)

Cost of goods sold

789.0k

Gross profit

16.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

392.9k147.1k10.4m4.4m577.8k871.4k5.4m7.2m1.3m4.8m1.8m1.7m2.1m2.0m1.7m1.7m1.8m2.1m2.1m2.4m2.5m2.4m2.8m1.8m2.1m2.9m2.7m2.4m2.2m2.3m3.1m2.1m

General and administrative expense

1.9m1.9m2.8m2.3m2.5m2.6m2.9m2.8m2.8m2.9m2.7m3.5m3.4m2.8m3.6m3.4m4.7m3.5m3.8m3.4m4.0m3.6m4.1m3.1m2.5m2.9m3.6m4.1m5.7m

R&D expense

3.1m3.0m5.2m4.5m3.0m2.6m3.2m121.9k3.1m3.3m3.7m4.7m5.9m4.0m6.8m8.8m6.8m13.5m11.3m13.4m8.3m6.5m5.0m4.1m5.6m5.1m7.5m6.8m11.4m

Operating expense total

5.0m5.0m8.0m6.8m5.5m5.2m6.1m7.1m6.0m6.3m6.4m8.2m9.3m6.9m10.4m12.3m11.5m17.1m15.1m16.8m12.2m10.1m9.1m7.2m8.1m8.0m11.1m10.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

15.1m12.7m9.6m7.7m33.1m26.0m38.3m23.6m15.4m129.6m40.0m

Accounts Receivable

42.1k908.1k1.5m2.0m2.1m2.5m3.1m2.9m3.2m3.0m3.2m

Prepaid Expenses

743.8k390.6k495.3k489.8k1.2m989.0k827.0k1.1m1.2m3.3m

Inventories

1.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

6.8m11.9m14.7m12.1m7.8m9.7m9.7m13.8m7.9m10.2m7.9m23.5m31.5m28.7m14.7m8.6m20.7m42.4m26.7m49.8m24.7m30.5m25.6m42.8m27.2m21.4m12.5m23.6m111.0m75.0m53.0m18.5m

Accounts Receivable

99.5k137.3k339.8k318.3k548.4k764.4k863.2k1.2m1.4m4.8m1.8m1.8m2.1m2.3m1.7m1.9m1.9m2.2m2.2m2.5m2.5m2.5m2.9m1.8m2.1m2.9m2.5m2.5m2.2m2.4m3.0m2.1m

Prepaid Expenses

475.1k676.0k351.3k397.1k498.1k398.5k413.5k505.1k501.7k363.4k655.8k828.3k777.4k818.2k928.4k975.0k1.4m1.2m958.0k1.2m909.0k776.0k1.1m681.0k819.0k1.6m1.3m1.0m3.3m1.6m3.1m3.4m

Current Assets

33.3m29.2m45.7m45.4m42.2m51.7m58.4m64.9m59.6m61.0m57.1m102.6m102.1m96.6m75.8m64.5m56.6m64.4m54.4m73.0m51.9m43.7m34.8m45.4m38.4m32.7m16.5m27.3m161.9m156.5m135.0m126.1m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(9.9m)(16.4m)(12.3m)(18.7m)(59.0m)(60.4m)(53.3m)(32.1m)(45.4m)

Depreciation and Amortization

107.4k126.5k141.5k155.1k160.8k193.0k125.0k144.0k

Accounts Payable

416.2k20.3k181.8k360.9k1.8m2.3m(376.0k)(1.9m)60.0k1.0m5.0m

Cash From Operating Activities

(4.6m)(15.2m)(9.5m)(16.8m)(29.9m)(35.8m)(48.4m)(30.1m)(26.2m)(25.7m)(37.6m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(11.7m)(15.9m)2.2m(660.7k)(4.0m)(5.0m)(6.3m)(8.1m)(5.6m)(7.5m)(13.0m)(31.8m)(40.0m)(45.5m)(9.4m)(20.7m)(49.1m)(15.7m)(29.8m)(45.3m)(10.7m)(19.4m)(26.6m)(9.9m)(17.1m)(9.7m)(16.4m)(9.9m)(20.8m)(31.8m)

Depreciation and Amortization

45.1k76.8k30.4k60.4k91.4k34.2k67.7k104.4k37.0k74.8k114.1k41.5k82.4k123.1k34.3k90.0k141.0k55.0k113.0k176.0k53.0k99.0k139.0k35.0k67.0k97.0k25.0k64.0k43.0k84.0k120.0k36.0k

Accounts Payable

(117.8k)95.1k(5.5k)(273.3k)170.0k(442.9k)133.8k436.4k(159.1k)395.2k345.5k(441.2k)(154.0k)75.6k49.9k(346.0k)1.1m(1.1m)2.1m78.0k(1.1m)(674.0k)(1.9m)(2.9m)(2.6m)(2.0m)(689.0k)107.0k(2.3m)(557.0k)1.0m(3.9m)

Cash From Operating Activities

(8.8m)(13.3m)4.3m2.7m(1.5m)(4.3m)(4.3m)(4.0m)(5.3m)(10.0m)(12.1m)(7.8m)(14.5m)(19.0m)(8.0m)(18.8m)(26.4m)(15.1m)(24.4m)(40.8m)(10.0m)(16.9m)(25.1m)(10.6m)(12.7m)(20.6m)(9.0m)(14.1m)(13.2m)(19.8m)(29.4m)(16.8m)
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Curis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

Learn more about our premium products
SecurityScorecard logo

Curis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Curis Online and Social Media Presence

Curis's Trends

Embed Graph

Curis Company Culture

  • Overall Culture

    B-

    78/100

  • CEO Rating

    A

    83/100

  • Compensation

    B

    81/100

Learn more on Comparably

Curis News and Updates

July 29, 2022

Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 29, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of...
July 28, 2022

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

LEXINGTON, Mass., July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2022 financial results on Thursday,...
June 10, 2022

Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress

Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response to emavusertib Promising clinical and preclinical analysis showcases the potential of...
April 04, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Curis, Inc. – CRIS

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ: CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
April 04, 2022

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

LEXINGTON, Mass., April 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the...
January 03, 2022

Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are...
Show more

Curis Blogs

June 10, 2022

Curis Emavusertib pCNS lymphoma EHA 2022

The post Curis Emavusertib pCNS lymphoma EHA 2022 appeared first on Curis, Inc.
June 10, 2022

Curis TakeAim Lymphoma EHA 2022

The post Curis TakeAim Lymphoma EHA 2022 appeared first on Curis, Inc.
June 04, 2022

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

June 03, 2022

Curis Emavusertib Phase 1 Gastric ASCO 2022

The post Curis Emavusertib Phase 1 Gastric ASCO 2022 appeared first on Curis, Inc.
June 02, 2022

Curis to Present at 2022 Jefferies Global Healthcare Conference

June 01, 2022

Curis IRAK4 Preclinical Poster EULAR 2022

The post Curis IRAK4 Preclinical Poster EULAR 2022 appeared first on Curis, Inc.
Show more

 Curis Frequently Asked Questions

  • When was Curis founded?

    Curis was founded in 2000.

  • Who are Curis key executives?

    Curis's key executives are Rachel Blasbalg, Kenneth I. Kaitin and John Hohneker.

  • How many employees does Curis have?

    Curis has 31 employees.

  • What is Curis revenue?

    Latest Curis annual revenue is $10.6 m.

  • What is Curis revenue per employee?

    Latest Curis revenue per employee is $343.5 k.

  • Who are Curis competitors?

    Competitors of Curis include Intrepida Bio, Ionova Life Science and Verseau Therapeutics.

  • Where is Curis headquarters?

    Curis headquarters is located at 4 Maguire Rd, Lexington.

  • Where are Curis offices?

    Curis has an office in Lexington.

  • How many offices does Curis have?

    Curis has 2 offices.